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Background: Histamine H3 receptor (H3R) is a potential therapeutic target of sleep- and cognition-related disorders.
The purpose of the present study is to develop a novel positron emission tomography (PET) ligand for H3Rs from
dihydroquinolinone derivatives, which we previously found to have high affinity with these receptors.
Methods: Six compounds were selected from a dihydroquinolinone compound library based on structural
capability for 11C labeling and binding affinity for H3Rs. Their in vivo kinetics in the rat brain were examined in a
comparative manner by liquid chromatography and tandem mass spectrometry (LC-MS/MS). Chemicals with
appropriate kinetic properties were then labeled with 11C and evaluated in rats and monkeys using PET.
Results: Of the six compounds, TASP0410457 (also diminutively called TASP457) and TASP0434988 exhibited fast
kinetics and relatively high brain uptakes in ex vivo LC-MS/MS and were selected as candidate PET imaging agents.
PET data in rat brains were mostly consistent with LC-MS/MS findings, and rat and monkey PET scans demonstrated
that [11C]TASP0410457 was superior to [11C]TASP0434988 for high-contrast H3R PET imaging. In the monkey brain
PET, distribution volume for [11C]TASP0410457 could be quantified, and receptor occupancy by a nonradioactive
compound was measurable using this radioligand. The specific binding of [11C]TASP0410457 to H3Rs was confirmed
by autoradiography using rat and monkey brain sections.
Conclusions: We developed [11C]TASP0410457 as a radioligand enabling a robust quantification of H3Rs in all brain
regions and demonstrated the utility of ex vivo LC-MS/MS and in vivo PET assays for selecting appropriate imaging
tracers. [11C]TASP0410457 will help to examine the implication of H3Rs in neuropsychiatric disorders and to
characterize emerging therapeutic agents targeting H3Rs.
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Histaminergic neurotransmission in the brain appears to
play roles in drinking and feeding, learning and memory,
and wake and sleep [1, 2]. Histamine H3 receptor (H3R)
acts as either presynaptic autoreceptor or heteroreceptor,
producing negative feedback regulation of histamine re-
lease or regulating release of non-histamine neurotrans-
mitters including glutamate, norepinephrine, dopamine,
and serotonin [3–6]. Therefore, H3R can be a potential
therapeutic target for various diseases such as sleep-
wake disorders including narcolepsy, attention-deficit
hyperactivity disorder, Alzheimer’s disease, and schizo-
phrenia [7–9].
Positron emission tomography (PET) imaging tech-
niques offer analytical approaches for examining neurore-
ceptor systems. Neuroreceptor ligands applicable to PET
imaging could provide tools to investigate alterations in
specific neurotransmissions under pathological conditions
and to quantify the receptor occupancy by therapeutic
agents. However, developing PET ligands for new targets
has often been challenging, as an appropriate PET ligand
needs to satisfy several criteria including the following
properties: sufficient binding affinity and selectivity for the
target receptor, adequate lipophilicity and molecular size
for blood–brain barrier penetration, minimal interference
of radiometabolites with imaging assays, low nonspecific
binding, presence of a radiolabeling sites, and sufficiently
fast kinetics in the brain [10].
Two compounds have been used to image central
H3Rs in clinical PET studies. GSK189254, a benazepin
derivative, is an inverse H3R agonist developed to im-
prove cognitive functions in Alzheimer’s disease [5]
and was labeled with 11C for PET imaging of H3Rs.
[11C]GSK189254 could visualize H3Rs in the human
brains, but its slow kinetics impeded accurate quanti-
fication of the available binding sites in brain regions
with high-level H3R expression [11]. MK-8278, a spiro-
isobenzofuranone derivative, and an inverse agonist with
high potency to H3Rs as well [12], was also labeled with
11C. [11C]MK-8278 showed more favorable kinetics than
[11C]GSK189254 [13], although it still remains to be estab-
lished whether the specific binding of this radioligand
reaches an equilibrium state within the PET image ac-
quisition time. Although these ligands were used for clin-
ical trials to quantitatively estimate occupancy of H3Rs
[11, 13–15], an additional new PET ligand with appropri-
ate pharmacokinetic, metabolic, and binding characteris-
tics can be developed along with a suitable method for
quantitative determinations of kinetic parameters.
Ex vivo assays of an exogenously administered com-
pound in tissues by liquid chromatography and tandem
mass spectrometry (LC-MS/MS) have been used to
evaluate kinetics of compounds in the brain without
radiolabeling and to predict the capability of compoundsas PET radioligands for several target molecules, such as
opioid κ receptor and nociception/orphanin FQ receptor
[16–20]. With this method, it is possible to select candi-
date compounds with preferable in vivo kinetics with a
relatively high throughput. The recent advances of the
LC-MS/MS device have also offered highly sensitive
measurements of compound retaining in the brain fol-
lowing administration at a dose nearly equivalent to PET
studies (approximately 2 to 10 μg/kg).
Here, we developed a novel PET ligand for H3Rs from
dihydroquinolinone derivatives, which were shown to
exert high affinity for H3Rs in our previous work [21].
Six compounds were initially selected from a library of
dihydroquinolinone analogs in consideration of the pres-
ence of 11C labeling site and binding reactivity with
H3Rs. Then, the pharmacokinetics of these candidate
compounds in the rat brain were compared by ex vivo
LC-MS/MS assays. Based on these kinetic data, two
compounds were chosen for labeling with 11C and were
evaluated in rats and monkeys using PET. A compound
that exhibited more favorable kinetics and higher im-
aging contrast for H3Rs in the brain was considered as
the best radioligand, and its utility in receptor occupancy
studies was further demonstrated by PET in monkeys.
Methods
Chemicals













410427) were synthesized at Taisho Research Laboratories
(Saitama, Japan). Procedures for synthesizing TASP0390
136, TASP0410457, and TASP0434988 and precursors
for 11C-labeling of these compounds are provided in
Additional file 1: Supplemental methods. Thioperamide
maleate and ciproxifan hydrochloride were purchased
from Sigma-Aldrich (St. Louis, MO). Clobenpropit was
purchased from Tocris Bioscience (Bristol, UK).
In vitro binding of compounds to H3Rs
Rat cerebral cortex and monkey frontal cortex were
dissected, homogenized with 50 mM Tris buffer (pH
7.4) containing 5 mM EDTA and Protease Inhibitor
Cocktail Tablets (Roche Diagnostics, Indianapolis, IN)
Fig. 1 Radiosynthesis of [11C]TASP0390136, [11C]TASP0410457, and [11C]TASP0434988, and chemical structure of TASP0390174, TASP0410426,
and TASP0410427
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lets were then suspended in binding buffer (50 mM Tris
containing 5 mM EDTA, pH 7.4) and stored at −80 °C as
membrane preparations.
The membrane preparations were thawed and incu-
bated in the binding buffer containing 0.1 % bovine serum
albumin, 1 nM [3H]N-α-methylhistamine (PerkinElmer,
Waltham, MA) with various concentrations of a dihydro-
quinolinone derivative (i.e., test compound) at 25 °C for
1 h. The reaction was terminated by rapid filtration
through 96-well GF/C filter plates (PerkinElmer) presoaked
with 0.5 % polyethyleneimine (Wako, Osaka, Japan). After
washes with ice-cold binding buffer, the plates were dried
and filled with Microscint-o (PerkinElmer). The radioactiv-
ity retained on the filters was counted using a TopCount
NXT (PerkinElmer). Total and nonspecific radioligand
binding was determined by reaction without and with
10 μM thioperamide and clobenpropit, respectively.
The specific radioligand binding was then calculatedby subtracting the nonspecific binding from the total
binding. The IC50 value for inhibition of the radioligand
binding by the test compound was determined using a
nonlinear fit of the concentration-response curve for each
test compound using SAS 9.2 (SAS Institute Inc., Cary,
NC). Data were expressed as the geometric means of
IC50 values from three independent experiments run
in duplicate.
Other in vitro profiling of compounds
Lipophilicity, off-target binding, and P-glycoprotein-
mediated efflux were determined as described in Additional
file 1: Supplemental methods.
Ex vivo pharmacokinetic assessments of compounds in
the rat brain using LC-MS/MS
The procedures of this animal experiment were re-
viewed and approved by the Animal Care Committee
of Taisho Pharmaceutical Co., Ltd. Six-week-old male
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(Yokohama, Kanagawa, Japan).
The rats were decapitated at 5, 15, 30, 60, and 120 min
after intravenous administration of TASP0390136, TASP0
390174, TASP0410426, TASP0410427, TASP0410457, or
TASP0434988 at a dose of 10 μg/kg. The cerebellum and
forebrain, including the medial prefrontal and cingulate
cortices and anterior striatum, were dissected and homog-
enized with four volumes of distilled water. The homoge-
nates were protein-precipitated with methanol/acetonitrile
(1:9) and were centrifuged at 3974×g for 10 min at 4 °C.
The resultant supernatants were injected into an HPLC
(Shimadzu-20AD, Shimadzu, Kyoto, Japan) and a tandem
mass spectrometer (API4000, AB SCIEX, Framingham,
MA) using a Shim-pak XR-ODS column (3.0 × 30 mm,
Shimadzu) at 50 °C. TASP0410457 was eluted with a
mobile phase consisting of 10 mM of ammonium
acetate/acetonitrile with a linear gradient at a flow rate of
1.3 mL/min, and ammonium formate instead of am-
monium acetate was used for eluting the other five
compounds. This modification was effective only for
assaying TASP0410457, resulting in the reduction of the
low limit of quantification but did not improve the detec-
tion of other five compounds. The eluted TASP0390136,
TASP0390174, TASP0410426, TASP0410427, TASP0410
457, and TASP0434988 were ionized using an electrospray
interface and were detected using reaction monitoring of
the transitions of m/z 395 to 91, 395 to 98, 413 to 98, 425
to 98, 408 to 138, and 407 to 138, respectively. A dihy-
droquinolinone compound (6-[(1-cyclobutylpiperidin-4-
yl)oxy]-1-(3,5-difluorophenyl)-3,4-dihydroquinolin-2(1H)-
one) was used as an internal standard for all assays. The
lower qualification limit for TASP0410457 was 0.05 ng/g
tissue, and the limit for the other five compounds was
0.15 ng/g tissue. Data were expressed as standardized
uptake values (SUVs) calculated as follows:
SUV ¼ tissue concentration g=gð Þ  body weight gð Þ
injected dose gð Þ
Radiochemical synthesis
[11C]TASP0390136, [11C]TASP0410457, and [11C]TASP0
434988 were synthesized as shown in Fig. 1a–c (detailed pro-
cedures are described in Additional file 1: SupplementalTable 1 Summary of radiosynthesis
Radiochemical yieldab (%) Average synthesis tim
[11C]TASP0390136 10.1 ± 3.1 29
[11C]TASP0410457 1.7 ± 0.3 29
[11C]TASP0434988 15.5 ± 4.6 29
aMean ± S.E.M., n = 3–8
bBased on [11C]CO2 obtained by bombardment with decay-uncorrected at the end
cData at EOSmethods) using a homemade automated synthesis system
[22]. The radiochemical purities and specific activities of the
radioligands, which were analyzed as described in Additional
file 1: Supplemental Methods, along with their radiochemical
yields and average synthesis times, are summarized in Table 1.
Analytical HPLC chromatogram of each radioligand is
shown in Additional file 2-4: Figures S1-S3. The radiochem-
ical stabilities of [11C]TASP0410457 and [11C]TASP0434988
in the final formulation were >99 % at 1 h and 40 min,
respectively, after the end of radiosynthesis.
PET imaging of rat brains
All PET experiments using animals were approved by
the Committee for the Care and Use of Laboratory
Animals of the National Institute of Radiological Sci-
ences (NIRS).
Six-week-old male Sprague-Dawley rats were purchased
from Japan SLC (Shizuoka, Japan). PET scans were per-
formed using a microPET Focus 220 small-animal scanner
(Siemens Medical Solutions USA, Knoxville, TN) [23].
The rats were anesthetized with 1.5–2 % isoflurane during
the imaging session, while their heart rate and blood
oxygen saturation were monitored by pulse oximeter
(CANL-425SVA; Med Associates, St. Albans, VT). Body
temperature was kept at 37 °C with a heating pad (BWT-
100; Bio Research Center, Aichi, Japan). Following the
transmission scans for attenuation correction using a
68Ge-68Ga point source, emission scans were performed
for 90 min in 3D list-mode with an energy window of
350–750 keV, immediately after the intravenous injection
of each radioligand. Mean ± S.D. of the injected radio-
activity of [11C]TASP0410457, [11C]TASP0434988, and
[11C]TASP0390136 was 119 ± 26 MBq, 132 ± 34 MBq, and
124 ± 17 MBq, respectively (n = 3–5). Mean ± S.D. of the
mass doses of [11C]TASP0410457, [11C]TASP0434988,
and [11C]TASP0390136 was 2.4 ± 1.2 μg/kg, 1.9 ± 0.4 μg/kg,
and 4.2 ± 1.6 μg/kg, respectively (n = 3–5).
To assess the specificity of radioligand binding, thio-
peramide was injected intravenously at a dose of 10 mg/kg
at 30 s before the injection of each radioligand.
Analyses of rat PET data
All list-mode data were sorted into 3D sinograms,
which were then Fourier rebinned into 2D sinograms
(frames: 1 min × 4, 2 min × 8 and 5 min × 14). Imagese (min) Specific activityac (GBq/mol) Radiochemical purityc (%)
95 ± 23 >98
104 ± 7 >98
111 ± 16 >98
of synthesis (EOS)
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with a 0.5-mm Hanning filter.
PET image and magnetic resonance imaging (MRI)
template were co-registered using PMOD software
(PMOD version 3.206; Zurich, Switzerland) according to
the following procedure as in our previous works: Out-
line of the whole brain and positions of eyes in PET im-
ages at an early phase of the scan were initially matched
to those in MRI images, and then further translations
and rotations of PET images were manually performed for
fine alignments. Finally, parameters for the co-registration
were applied to the entire dynamic PET data. Regions of
interest (ROIs) were placed on the striatum, hippocampus,
and cerebellum using PMOD software with reference to
the MRI template as described elsewhere [24]. The tissue
time-activity curves (TACs) for these ROIs were generated
by calculating the SUV for each time frame as follows:
SUV ¼ radioactivity Bq=gð Þ  body weight gð Þ
injected radiotracer dose Bqð Þ
The binding potentials relative to the non-displaceable
uptake (BPND) in the striatum and hippocampus were esti-
mated using the simplified reference tissue model (SRTM)
[25] with PMOD software using the cerebellum as a refer-
ence region, as the rat cerebellum is devoid of H3R [26].
PET study in monkeys
A male rhesus monkey (Macaca mulatta, weighing
6–7 kg) was used for a comparative PET analysis of
[11C]TASP0410457 and [11C]TASP0434988. PET scans
were performed using a high-resolution SHR-7700 animal
PET camera (Hamamatsu Photonics, Hamamatsu, Japan).
Following transmission scans for attenuation correction
using a 68Ge-68Ga point source, emission scans were per-
formed on a conscious monkey as described previously
[27], in 3D acquisition mode (frames: 10 s × 12, 30 s × 6,
1 min × 5, 2 min × 5 and 5 min × 14) for 90 min after
the intravenous injection of [11C]TASP0410457 (169–
176 MBq) or [11C]TASP0434988 (173–188 MBq). Briefly,
the monkey was immobilized by joining the acrylic cap on
the monkey head with the fixation device during PET
scans. To assess a homologous competition for the target
binding sites, unlabeled TASP0410457 or TASP0434988
was injected intravenously at a dose of 1 mg/kg at 30 s be-
fore injection of the corresponding radioligand.
For a detailed pharmacokinetic PET study using
[11C]TASP0410457 with arterial blood sampling, three
male rhesus monkeys weighing 5–7 kg were scanned
with the SHR-7700 PET camera. The monkeys were ini-
tially anesthetized with an intramuscular injection of
ketamine (10 mg/kg), intubated, and subsequently kept
anesthetized with 1–2 % isoflurane. Electrocardiogram
and blood oxygen saturation levels were monitored, andbody temperature was maintained by a heating pad
throughout the experiment. Arterial blood (1–2.5 mL)
was collected from the saphenous artery at 10, 20, 30,
40, 50, 60, and 90 s and at 2, 3, 4, 5, 10, 15, 30, 60, and
90 min after the intravenous injection of [11C]TASP0
410457 (injected radioactivity, 159 ± 30 MBq; mass dose,
1.2 ± 0.3 μg; mean ± S.D., n = 3).
The arterial blood was centrifuged at 20,000×g for
3 min at 4 °C to separate the plasma. Radioactivity in
total blood and plasma was determined using a 1480
WIZARD gamma counter (PerkinElmer), and was decay-
corrected to the injection time. Arterial plasma collected
at 1, 5, 15, 30, 60, and 90 min was used to analyze radio-
active metabolites of [11C]TASP0410457. Two hundred
microliters of plasma was mixed with 200 μL of ice-
cold acetonitrile, and the mixtures were centrifuged at
20,000×g for 3 min at 4 °C. Fifty to five hundred mi-
croliters of the resultant supernatants were separated
using HPLC (JASCO, Tokyo, Japan) on an Atlantis T3 col-
umn (4.6 × 50 mm, Waters, Milford, MA) with a mobile
phase consisting of 10 mM of ammonium acetate/aceto-
nitrile (68:32) at a flow rate of 1 mL/min. The fraction of
unmetabolized [11C]TASP0410457 was determined by
measuring the areas of the HPLC peaks correspond-
ing to [11C]TASP0410457 and its radiometabolites.
Analyses of monkey PET data
Emission scan images were reconstructed using a 4.0-
mm Colsher filter. ROIs were placed on the anterior
cingulate cortex, striatum, thalamus, hippocampus,
cerebellum, frontal cortex, temporal cortex, occipital
cortex, and pons-medulla using PMOD software, with
reference to an MRI template as described previously
[24]. Tissue TACs were generated as in the rat PET
image analysis.
For PET study in anesthetized monkeys, metabolite-
corrected plasma TACs were used as arterial input func-
tions. The regional total volume of distribution (VT) was
estimated by Logan’s graphical plot and one-tissue com-
partment model using PMOD software.
Receptor occupancy assays
Occupancy of central H3Rs by ciproxifan, a selective an-
tagonist/inverse agonist, was quantified by [11C]TASP
0410457-PET scans of an anesthetized monkey with ar-
terial blood sampling. Ciproxifan was injected at a dose
of 3 mg/kg intravenously at 10 min before the injection
of [11C]TASP0410457. Receptor occupancy of ciproxifan
was determined using Lassen’s plot without any refer-
ence regions using the following equation:
VT




Ciproxifan are the regional VT
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spectively, VND is the non-displaceable distribution vol-
ume, and Occ is the occupancy [28].
Autoradiography of [11C]TASP0410457 using rat and
monkey brain sections
Twenty-micrometer-thick sagittal rat and monkey brain
sections were incubated in an autoradiography buffer
containing 5 nM [11C]TASP0410457 as described in
Additional file 1: Supplemental methods. The binding
was also performed in the presence of 10 μM of un-
labeled TASP0410457, thioperamide, or ciproxifan for
the rat sections and 10 μM of TASP0410457 or ciproxi-
fan for the monkey sections to assess the specific radioli-
gand binding.
Results
Selection of candidate compounds for PET imaging
Six compounds, TASP0410457, TASP0434988, TASP039
0136, TASP0390174, TASP0410426, and TASP0410427,
were initially selected from our dihydroquinolinone
compound library, since they fulfilled the following cri-
teria for a PET radioligand candidate: (1) the presence of
a methoxy group or other moieties for 11C or 18F label-
ing and (2) high binding affinity for rat H3R (IC50 <
3 nM). The kinetics of these compounds in the rat brain
were then pursued by ex vivo LC-MS/MS measurementsa b
d e
Fig. 2 Pharmacokinetics of non-radiolabelled compounds in the rat brain.
TASP0390136 (c), TASP0390174 (d), TASP0410426 (e), and TASP0410427 (f)
determined by ex vivo LC-MS/MS after the intravenous administration of 1
120 min in the plots indicates that the concentration measures were belowof non-labeled compounds in brain tissues collected at
different time points after bolus intravenous administra-
tion (Fig. 2). The ranked order of the peak concentration
of these compounds in the forebrain including striatum
enriched with H3Rs was TASP0410457 > TASP0434988 >
TASP0390136 ≈ TASP0390174 ≈ TASP0410426 > TASP0
410427 (Fig. 2). Mean peak concentrations of TASP0
410457, TASP0434988, TASP0390136, TASP0390174,
TASP0410426, and TASP0410427 in the forebrain ex-
pressed as SUV were 0.85, 0.58, 0.30, 0.28, 0.30, and
0.10, respectively (Fig. 2). The concentrations of all six
compounds in the forebrain were higher than those in
the cerebellum devoid of H3Rs throughout the pharma-
cokinetic tracking.
TASP0410457 and TASP0434988 were selected as can-
didates for a PET radioligand, because they exhibited
rapid entry into the brain followed by fast washout
(Fig. 2a, b) and the highest and second highest uptakes,
respectively, in the forebrain versus the cerebellum.
TASP0390136 was also chosen for radiolabeling as a
control compound with insufficient brain uptake in
order to assess the consistency between ex vivo LC-MS/
MS and in vivo PET data.
We then revisited the in vitro properties of these three
compounds in search of chemical determinants of
in vivo pharmacokinetic performance of test ligands in
the brain. The three compounds showed high in vitroc
f
a–f The concentrations of TASP0410457 (a), TASP0434988 (b),
in the forebrain (closed circles) and cerebellum (open circles) were
0 μg/kg of the compound in rats. The absence of symbols at 60 or
the lower limit of quantification. Data are mean ± S.E.M (n = 3)
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displayed more than 60 times higher selectivity for H3R
than off-target binding components including sigma 1, ad-
renergic α2c receptors, and 67 other molecules (Additional
file 1: Table S1). Lipophilicity of these chemicals was
slightly low to moderate as CNS-targeting compounds
(Table 2). Based on the susceptibility for P-glycoprotein
with an assumed criterion for efflux ratio (ER) exceeding
2.00, TASP0410457 was not a substrate of P-glycoprotein
(ER: 1.64), while TASP0390136 and TASP0434988 turned
out to be P-glycoprotein substrates (ER: 6.29 and 2.14, re-
spectively). It should be noted that the ex vivo LC-MS/MS
measures were only partly correlated with the susceptibil-
ity of the compounds for human P-glycoprotein. Indeed,
uptakes of TASP0390136 and TASP0434988 in the cere-
bellum were similar despite a large difference in the ER es-
timate (Fig. 2b, c). Hence, diverse factors determining the
permeability of chemicals into the brain, including species
difference in P-glycoprotein and contributions other efflux
transporters, should also be taken into account.
PET imaging of the rat brain with [11C]TASP0410457 and
[11C]TASP0434988 versus [11C]TASP0390136
PET scans of rats demonstrated high radioactivity signals
in the striatum after a bolus intravenous administration
of [11C]TASP0410457 (Fig. 3a) with a peak SUV approxi-
mating 2.0, and the hippocampus and cerebellum exhib-
ited moderate and low signals with SUVs peaking at
around 1.5 and 1.2, respectively (Fig. 4a), in agreement
with the known distribution of H3R. Although the peak
uptake of [11C]TASP0434988 in the cerebellum was only
slightly lower than that of [11C]TASP0410457, striatal
and hippocampal peak SUVs for [11C]TASP0434988
were 20–25 % lower than those for [11C]TASP0410457
(Figs. 3b, 4b). [11C]TASP0390136 yielded profoundly
lower signals in all brain regions than the other two radi-
oligands (Figs. 3c, 4c), in accordance with ex vivo LC-MS/
MS observations.
The regional differences in radioactivity were abolished
by the pretreatment with 10 mg/kg of thioperamide, an
H3R antagonist (Figs. 3d–f, 4d–f ), or 1 mg/kg of unlabeled
corresponding compounds (data not shown). The cerebel-
lar kinetics of each radioligand was not noticeably altered
by these pretreatments (Fig. 4a–f ), indicating the availabil-
ity of the cerebellum as a reference region for quantitativeTable 2 In vitro properties of TASP0390136, TASP0410457, and TASP
Affinity for H3Rs Off-targ
Rat, IC50 Monkey, IC50 Sigma 1
nM (n = 3) nM (n = 3) nM
TASP0390136 2.74 1.06 167
TASP0410457 2.34 1.80 379
TASP0434988 0.783 0.565 257analyses in rats. Indeed, cerebellar SUVs at 15 min after
radioligand injection at baseline and thioperamide pre-
dosing were 0.64 ± 0.13 and 0.47 ± 0.09, respectively, for
[11C]TASP0410457, 0.64 ± 0.04 and 0.59 ± 0.02, respect-
ively, for [11C]TASP0434988, and 0.33 ± 0.01 and 0.30 ±
0.03, respectively, for [11C]TASP0390136 (mean ± S.D.).
Target-to-reference ratios of the radioligand retention
indicated that the specific binding of [11C]TASP0410457
and [11C]TASP0434988 reached a pseudo-equilibrium
state within 15 min after intravenous injection (Fig. 4g, h).
The specific binding of [11C]TASP0410457 determined as
BPND was 25–30 % higher than that of [
11C]TASP0434988
in the striatum and hippocampus (Table 3).
The regional brain kinetics of the three compounds
exhibited by PET was mostly consistent with the ex vivo
LC-MS/MS results. The ranked order of peak radioligand
uptakes in the striatum agreed with the order in the
forebrain determined by LC-MS/MS (TASP0410457 >
TASP0434988 > TASP0390136; Fig. 2a–c versus Fig. 4a–c).
Meanwhile, the cerebellar peak radioligand uptakes assayed
by PET but not ex vivo LC-MS/MS were inversely corre-
lated with the ER values of the compounds. As a conse-
quence, the LC-MS/MS analysis seemed to overestimate
the specific binding (difference in SUV between the target
reference regions) of TASP0434988 as compared with the
quantification by PET.
Comparative PET imaging of monkey brains with
[11C]TASP0410457 and [11C]TASP0434988
Radioactivity signals in the monkey striatum and anter-
ior cingulate cortex were intensified after the bolus
intravenous administration of [11C]TASP0410457 and
[11C]TASP0434988 (Fig. 5a, c). The uptake of [11C]TA
SP0410457 peaked within 30 min after the injection,
followed by a gradual decline (Fig. 5f ), and [11C]TA
SP0434988 underwent a slightly slower washout from
the brain than [11C]TASP0410457 (Fig. 5h). Radioactivity
in all ROIs, including the cerebellum and pons/medulla,
was decreased by pretreatment with unlabeled corre-
sponding compounds (Fig. 5b, d, g, and i), indicating
that the radioligand binding was saturable and specific
and that no brain areas in the monkey were available
as reference regions for quantifications. The difference
in regional radioligand retention beyond 30 min be-












Fig. 3 In vivo PET images of [11C]TASP0410457, [11C]TASP0434988, and [11C]TASP0390136 in the rat brain. Average sagittal PET images at
0–90 min after intravenous administration of [11C]TASP0410457 (top), [11C]TASP0434988 (middle), and [11C]TASP0390136 (bottom) at baseline (a–c)
and after pretreatment with 10 mg/kg of thioperamide (d–f). The PET images were overlaid on an MRI template
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PET (Fig. 5), supporting the advantage of [11C]TASP0
410457 over [11C]TASP0434988 for high-contrast imaging
of central H3Rs. We accordingly chose [
11C]TASP0410457
for further characterizations as a radioligand with the
highest in vivo performance.
Quantitative analyses of [11C]TASP0410457-PET data in
monkeys
The uptake of [11C]TASP0410457 in the brain was
quantified with arterial blood sampling in anesthetized
monkeys. Plasma radioactivity rapidly increased after
the injection, peaked at approximately 1 min, and then
promptly declined (Fig. 6a). A reverse-phase HPLC
analysis of the monkey plasma indicated that a major me-
tabolite of [11C]TASP0410457 (the first peak in Fig. 6b)
with a retention time corresponding to the holdup time
was more polar than the parent compound (the second
peak in Fig. 6b). The fraction of unmetabolized [11C]TA
SP0410457 decreased over time, accounting for 34 % of
total plasma radioactivity at 90 min (Fig. 6c). Radioligand
retention was increased particularly in H3R-rich brain
areas of these anesthetized monkeys (Fig. 6d) relative to a
conscious monkey (Fig. 5f), implying anesthetic-induced
enhancement of radioligand binding. To examine this
possibility, we carried out an additional PET study using
another monkey in a conscious condition. The peak SUV
in the striatum of this monkey was 3.0 and was similar to
the value (3.4) in the first conscious monkey. These values
were below mean–2S.D. in anesthetized monkeys (5.0 ±
0.8, mean ± S.D.), further supporting effects of anesthesia.
However, radioligand retention peaked at around 30 min
in the striatum of anesthetized monkeys, which wassimilar to the kinetics in the awake monkey. A time-
stability examination demonstrated that the progressive
truncation of the PET data had relatively small but notice-
able effects (within 7 % of the values for 90 min) on the
VT values estimated by Logan’s graphical analysis when
the endpoint of the sampling time interval was changed
from 90 to 60 min (Table 4). We additionally calculated
VT values by a one-compartment model and obtained esti-
mates similar to the graphical plot results (Table 4).
Pretreatment by intravenous administration of an H3R
antagonist, ciproxifan, at a dose of 3 mg/kg substantially
reduced the radioactivity in all ROIs including the cere-
bellum and pons-medulla. Lassen’s plot displayed robust
linearity (Fig. 6e), demonstrating uniform receptor occu-
pancy among brain regions, and the receptor occupancy
of ciproxifan at this dose was stably estimated as ~75 %.
Non-displaceable distribution volume was estimated as
4.0 mL/cm3 (Fig. 6e), and thus, the specific radioligand
binding accounted for more than 80 % of the radioactivity
in the striatum, taking this result together with the finding
that the striatal VT exceeded 20 mL/cm
3 (Table 4). We
also treated a monkey with 10 mg/kg of ciproxifan but
could not complete PET imaging due to its profound ef-
fects on heart rates and body motions even in an anesthe-
tized condition with isoflurane.
Autoradiography of [11C]TASP0410457
In vitro autoradiograms of rat brain sections with
[11C]TASP0410457 illustrated the abundant specific
binding in the striatum and neocortex (Fig. 7a). Radio-
activity in the cerebellum and brainstem was low and not
markedly altered by homologous or heterologous block-




Fig. 4 a–f: TACs for [11C]TASP0410457 (top), [11C]TASP0434988 (middle), and [11C]TASP0390136 (bottom) in the rat striatum (circles), hippocampus
(rhombi), and cerebellum (triangles) at baseline (a–c) and after pretreatment with 10 mg/kg of thioperamide (d–f). g–i Temporal changes of
specifically bound [11C]TASP0410457 (g), [11C]TASP0434988 (h), and [11C]TASP0390136 (i) in the striatum (circles) and hippocampus (rhombi)
determined as ratios in SUVs between the target region and the cerebellum. Data are mean ± S.E.M (n = 3–5)
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was consistent with the in vivo PET data (Fig. 7e). [11C]T
ASP0410457 binding in the monkey cerebellum and
brainstem was noticeably decreased in the presence
of 10 μM of unlabelled TASP0410457 or ciproxifan
(Fig. 7f, g).
Discussion
The present work provides a clear demonstration that a
new PET radioligand with adequate binding and kineticTable 3 Regional BPND values for radioligands in rat PET
Striatum Hippocampus
[11C]TASP0410457 1.26 ± 0.12 0.53 ± 0.06
[11C]TASP0434988 0.92 ± 0.21 0.36 ± 0.11properties suitable for high-contrast and quantitative
PET assays of central H3Rs can be generated from dihy-
droquinolinone derivatives. Screening of non-radiolabeled
chemicals was carried out by the conjunctive use of infor-
mation from in vitro assays and ex vivo LC-MS/MS mea-
surements, resulting in the identification of two candidate
compounds. Subsequent in vivo PET analyses of rat and
monkey brains indicated the utility of these two li-
gands as imaging agents and revealed that the pyridi-
nated compound [11C]TASP0410457 yielded a higher
signal-to-background ratio, reflecting the abundance
H3Rs, and good linearity of Lassen’s graphical plot
across all examined brain regions, offering accurate quan-
titative measures of the receptor density at baseline and
under occupancy by a drug with a sufficient dynamic






Fig. 5 In vivo PET in a conscious rhesus monkey. a–e Average horizontal PET images at 30–90 min after the intravenous administration of
[11C]TASP0410457 (top) and [11C]TASP0434988 (bottom) at baseline (a, c) and after pretreatment with 1 mg/kg of unlabelled TASP0410457 (b) or
TASP0434988 (d), along with co-registered MR images of the monkey brain (e). f–i TACs for [11C]TASP0410457 (top) and [11C]TASP0434988
(bottom) in the anterior cingulate cortex (closed circles), striatum (open circles), hippocampus (closed triangles), cerebellum (open triangles), and
pons-medulla (squares) at baseline (left) and after pretreatment with 1 mg/kg of unlabelled compound (left)
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ASP457 is used in clinical works) has been applied to a
human PET study and has been demonstrated to permit
robust quantification of H3Rs in diverse brain regions
(Kimura et al., manuscript submitted to Eur J Nucl Med
Mol Imaging). These clinical data accordingly indicate the
validity of our translational workflow for the identification
of an appropriate H3R radioligand.
We employed ex vivo LC-MS/MS to select candidate
compounds for PET imaging, because this technique
has been successfully applied to label-free evaluationsof potential PET ligands for opioid κ receptor and
nociception/orphanin FQ receptor [16, 18]. Our present
data also verified the capability of LC-MS/MS measure-
ments in predicting in vivo performances of the H3R li-
gands when employed for PET examinations. Indeed, the
relative order of ligand uptake in the rat forebrain deter-
mined by LC-MS/MS was overall in good agreement with
the observations in rat PET. In light of the present and
previous [16–20] demonstrations, LC-MS/MS quantifica-
tions of ex vivo samples can serve for capturing kinetic





Fig. 6 In vivo PET in anesthetized rhesus monkeys with acquisition of an arterial input function. a–c Representative plasma TAC (closed circles)
and metabolite-corrected arterial input function (open circles) in a monkey (a), a representative radio-HPLC chromatogram of the protein-precipitated
monkey plasma at 30 min after an administration of [11C]TASP0410457 (b) and time course of changes in the ratio of unmetabolized [11C]TASP0410457
in plasma (c; mean ± S.E.M, n = 3). d TACs in the striatum (circles) and pons-medulla (triangles) at baseline (closed symbols) and after pretreatment with
3 mg/kg of ciproxifan (open symbols) obtained in a single monkey. e Lassen plot for determination of the occupancy of H3Rs by ciproxifan. A circle in
the Lassen plot denotes a value in each ROI, and a solid line represents regression
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discrepancy between ex vivo and in vivo measures was
also found in a small subset of data, including the peak
cerebellar uptake of TASP0434988. In addition, ex vivo
LC-MS/MS failed to determine concentrations of the
compounds at 60 and 120 min after administration, as
these values did not exceed the low limit of quantification
of MS (0.15 ng/g tissue). These issues may be attributed
to the sensitivity of the detection device and samplepreparation for LC-MS/MS, which will need further
improvements and optimizations.
It should also be considered that a radiometabolite of
[11C]TASP0410457 in plasma gradually entered the CNS
and raised PET signals in the brain while not affecting
LC-MS/MS detection of the parent compound. We per-
formed a preliminary analysis of metabolites in the rat
brain after injection of non-radiolabeled TASP0410457
and TASP0434988 using an HPLC and ion trapping MS
Table 4 Time-stability of regional VT values for [
11C]TASP0410457 in the monkey brain
Logan graphical analysis One-tissue compartment model
Scan duration (min) Scan duration (min)
Region 60 70 80 90 90
Striatum 21.2 ± 3.0 21.5 ± 3.0 21.9 ± 3.3 22.6 ± 3.8 23.2 ± 3.6
Anterior cingulate cortex 18.4 ± 2.7 18.6 ± 2.8 19.1 ± 3.2 19.5 ± 3.4 20.3 ± 3.3
Thalamus 15.1 ± 1.7 15.4 ± 1.9 15.6 ± 1.9 16.0 ± 2.1 16.1 ± 1.8
Hippocampus 13.0 ± 1.0 13.2 ± 1.0 13.6 ± 1.2 13.9 ± 1.4 13.9 ± 1.3
Frontal cortex 12.3 ± 1.6 12.5 ± 1.7 12.8 ± 1.8 13.0 ± 2.0 13.4 ± 1.8
Cerebellum 12.1 ± 1.2 12.4 ± 1.3 12.7 ± 1.5 13.0 ± 1.7 12.8 ± 1.7
Temporal cortex 12.3 ± 1.6 12.4 ± 1.7 12.5 ± 1.8 12.9 ± 2.1 13.3 ± 2.1
Occipital cortex 11.7 ± 1.6 11.8 ± 1.6 12.0 ± 1.8 12.1 ± 1.9 12.7 ± 2.0
Pons-medulla 8.5 ± 0.6 8.6 ± 0.7 8.8 ± 0.7 9.1 ± 0.9 8.8 ± 0.9
Mean ± S.D., n = 3
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was generated by desmethylation of each parent com-
pound at the 11C labeling site. Accordingly, it is likely
that the major metabolic pathway leads to the produc-
tion of a small, polar radiometabolite, such as [11C]for-
maldehyde, which is in accord with our HPLC analysis






Fig. 7 In vitro autoradiographic labeling of rat and rhesus monkey brain sli
sagittal rat brain sections without blockade (a) or with 10 μM of unlabelled
monkey brain sections without blockade (e) or with 10 μM of unlabelled Tpilot assays in mice have suggested that this metabolite
accounts for approximately 50 % of radioactivity in the
brain at 30 min after intravenous injection of [11C]TAS
P0410457 (K. Kawamura, personal communication, 2015).
In view of these factors potentially causing differences
between LC-MS/MS and PET data, a practical workflow
for the identification of the best PET ligand from an arrayces with [11C]TASP0410457. The images show radioligand bindings in
TASP0410457 (b), thioperamide (c), and ciproxifan (d) and in sagittal
ASP0410457 (f) or ciproxifan (g). Scale bar: 10 mm
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ing qualified kinetic properties in label-free ex vivo
assays, followed by the determination of a radiolabeled
ligand with the highest capability in rodent and non-
human primate PET imaging, as conducted in the
present work.
Our current results imply the applicability of [11C]TA
SP0410457 to investigations of H3Rs and evaluations of
drugs acting on these receptors in the living human
brain, which has been evidenced in clinical PET analyses
(Kimura et al., manuscript submitted to Eur J Nucl Med
Mol Imaging). Two radioligands, [11C]GSK189254 and
[11C]MK-8278, have been non-clinically and clinically
applied to quantify central H3Rs. Although [
11C]GSK
189254 exhibited sufficient brain uptakes, the kinetics of
this radioligand exhibited a continuous increase over
90 min, hampering the estimation of regional VT in the
baboon and human striatum [11, 14, 29]. [11C]MK-8278
displayed more preferable kinetics (a rapid increase
followed by a gradual decline in PET imaging time)
than [11C]GSK189254, and but its time-stability data of
VT in the human brain showed a gradual increase in
VT over time [13]. The present study indicated that
VT of [
11C]TASP0410457 in the monkey brain was
relatively stable over time but increased by 7 % at
maximum from 60 to 90 min, and this is presumably
due to gradually accumulating radiometabolites in the
brain but not stemming from slow kinetics of the
radioligand binding. Hence, dynamic PET scans ac-
quired for 60 min provide adequate quantitative mea-
sures of the radioligand kinetics in the monkey brain.
As mentioned above, the major metabolite accounted
for approximately 50 % of total radioactivity in the
mouse brain at 30 min after radioligand injection (K.
Kawamura, personal communication, 2015). In light of
the finding that 86 and 53 % of total plasma activity
in mice and monkeys, respectively, were derived from
the radiometabolite at 30 min, the entry of the radio-
metabolite in the monkey brain should be less promin-
ent than that in the mouse brain. Influences of the
radiometabolite on VT values in the human brain
would be even less profound, because only 13 % of
total plasma radioactivity at 30 min in humans arose
from a metabolite identical to the molecule detected
in animals (Kimura et al., manuscript submitted to
Eur J Nucl Med Mol Imaging). Correspondingly, our
clinical PET results showed smaller increase of VT
values along with extension of dynamic scan time from
60 to 90 min than the changes in a monkey (Kimura
et al., manuscript submitted to Eur J Nucl Med Mol
Imaging).
It is also noteworthy that pharmacokinetic evaluations
of H3R ligands were quantitatively performable in rats
using the cerebellum as a reference region lacking thetarget receptor. By contrast, the use of the cerebellum as
a reference region to quantify H3R in the human and
nonhuman primate brains remains to be revisited. A
clinical PET study [11C]GSK189254 indicated that VT
values for this radioligand were markedly reduced in all
ROIs including the cerebellum and pons by treatment
with an H3R ligand, AZD5213, and it is accordingly
likely that no reference region can be defined in the
human brain [14]. However, PET imaging of the monkey
and human brains with [11C]MK-8278 employed the
pons as a reference region to estimate the occupancy
of H3Rs by an antagonist/inverse agonist, MK-0249
[13, 30]. Our present data demonstrated the presence
of displaceable binding sites for [11C]TASP0410457
and [11C]TASP0434988 in the monkey cerebellum and
brainstem including the pons, similar to the previous
reports on [11C]GSK189254 [11, 14, 29]. This finding was
also consistent with the presence of specific binding com-
ponents for H3R ligands in the monkey cerebellum dem-
onstrated previously [30, 31]. Likewise, reference tissue
models may not be available for describing the kinetics of
[11C]TASP0410457 in the human brain, and thereby
Lassen’s plot of VT values estimated with an arterial
input function will be required for clinical assays of the
H3R occupancy by a drug.Conclusions
We developed a radioligand, [11C]TASP0410457, for a
robust quantification of H3Rs in all brain regions and
demonstrated the utility of ex vivo LC-MS/MS and
in vivo PET assays for selecting appropriate imaging
tracers from candidate compounds. In light of the
current data, [11C]TASP0410457 will facilitate clarifica-
tion of roles played by H3Rs in neuropsychiatric disor-
ders and characterizations of emerging therapeutic
agents acting on these receptors.Ethical approval
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